Special Issue "Tailored Treatments for Lung Cancer: From Early Diagnosis to Resistance Approaches in Advanced Stages"
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: 20 June 2023 | Viewed by 4777
Special Issue Editor
Interests: lung cancer; NSCLC; EGFR; tyrosine kinase inhibitors; targeted therapy; immunotherapy; oncogene addiction; co-mutation patterns; resistance mechanisms
Special Issue Information
Molecular advancements in the field of lung cancer have rapidly led to increased knowledge of tumor biology and a subsequent expansion of the horizons for the treatment of the biggest cancer-related killer worldwide.
In particular, the portfolio of actionable gene alterations that may function as potential therapeutic targets (so-called targetable gene alterations) is rapidly growing. In parallel, the emerging data regarding immunotherapy applicability in oncogene-addicted lung cancer make it mandatory to have complete molecular profiles together with PD-L1 statuses to better tailor treatment options. Of note, the impact of targeted and immune-based treatments is also being investigated in early-stage disease, with positive results. This knowledge requires the prompt improvement of testing, from early diagnosis to advanced disease, to allow patients to receive the best therapeutic option at any stage of their disease.
This Special Issue will highlight the current knowledge and future opportunities to tailor the treatment of lung cancer through clinical and translational research as a key to improve survival.
Dr. Antonio Passaro
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lung cancer
- immune checkpoint inhibitors
- targeted therapy
- tyrosine kinase inhibitors (TKI)
- resistance mechanisms
- next-generation sequencing
- molecular oncology
- liquid biopsy
- adjuvant treatment